Navigation Links
Groundbreaking Study Gives Hope For Patients With Kidney Cancer

German researchers have developed what appears to be an effective vaccine against recurrent kidney cancers.// Kidney cancer accounts for about 3 percent of all cancers and causes about 12,000 deaths in the United States every year. The disease most often strikes those in their 50s and 60s. Standard treatment involves removal of all or part of the kidney. Unlike some other cancers, however, kidney cancer does not respond well to subsequent treatment with chemotherapy or radiotherapy. About half of all patients diagnosed with the disease will have a recurrence after the initial surgery.

Scientists tested vaccines custom made using the individual tumors from kidney cancer patients. The study involved 558 patients scheduled for surgery for kidney cancer. About half the group received six vaccine injections at four-week intervals following surgery. The other half received no additional treatment .The patients were then followed for five years. Among the 379 patients for whom follow up data were available, 77 percent of those who received the vaccinations were still alive without a recurrence of the disease. This compares to 68 percent of those who did not receive the injections.

Researchers conclude saying that,such a milestone could serve as a concrete step towards making adjuvant treatment of renal cancer a routine and effective intervention.
'"/>




Page: 1

Related medicine news :

1. Groundbreaking Asthma Intervention Lessons Help Inner-City Children
2. Tomato Sauce reduces Cancer Risk- Study
3. Study on obesity and heart failure
4. National Lung Study in the process
5. Study casts doubt on keyboard ills
6. Study reveals how stress can make you sick
7. Study reveals how stress can make you sick
8. Study supports vegetable diet
9. Study to look at early surgery to treat epilepsy
10. Its Never Too Late to Stop Smoking,Study Finds
11. New Technique to Study Infants Brain.
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... Edinburg, Texas (PRWEB) , ... April 28, 2017 , ... ... a plaque in recently to the labor and delivery team at Women’s Hospital at ... generous mothers who give birth at the hospital and decide to donate. , ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... 28, 2017 , ... Bill Howe started his sewer and drain company in ... Howe joined the team, the Bill Howe brand was born and they began cultivating ... giving back to the San Diego community in which they worked, lived and were ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Texas , April 20, 2017  Vivify Health, ... mobile devices, has been awarded a very significant patent ... via EMRs to continual care via digital health.  This ... key intellectual property and further secures Vivify,s position as ... launched in 2009, was the first company to apply ...
(Date:4/20/2017)... WOONSOCKET, R.I. , April 20, 2017 /PRNewswire/ ... (NYSE: CVS), today unveiled a new store design ... new assortment of healthier food, health-focused products and ... the store to help customers discover new offerings. ... represent the next evolution of the customer experience ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: